This review discusses pathogenesis of MS and current treatments and evidence in support of the use of ozanimod, its pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials. It also provides commentary and recommendations from Clinical Associate Professor Todd Hardy, Staff Specialist Neurologist at Concord Hospital.
Please login below to download this issue (PDF)